(S)-3-(tert-butoxycarbonyl)-4-phenylbutanoic acid | 1093232-43-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S)-3-(tert-butoxycarbonyl)-4-phenylbutanoic acid
• 英文别名: (3S)-3-benzyl-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid
• CAS: 1093232-43-9
• 化学式: C₁₅H₂₀O₄
• 分子量: 264.321
• InChiKey: ZVZVJDYXMTUDLY-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 (S)-3-(tert-butoxycarbonyl)-4-phenylbutanoic acid 在 N-甲基吗啉 、 叔-丁基氯甲酸酯 、 氢溴酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Optical 2-benzyl-5-hydroxy-4-oxopentanoic acids against carboxypeptidase A: Synthesis, kinetic evaluation and X-ray crystallographic study

  摘要：

  2-Benzyl-5-hydroxy-4-oxopentanoic acid 1 and its enantiomers were designed, synthesized and assayed for inhibitory activity against carboxypeptidase A (CPA, EC 3.4.17.1). To verify the role of the terminal hydroxyl group in 1 binding to CPA, 2-benzyl-5-benzyloxy-4-oxopentanoic acid 2 was also synthesized and evaluated. The inhibition constants show that both L-1 and D-1 were shown to have strong binding affinity with L-1 being more potent than its enantiomer by 165-fold. On the other hand, the inhibition constant of 2 increases 4-fold comparing with that of 1. In order to explore the exact binding mode of the hydroxyacteyl group of 1 to the active site zinc ion of CPA, we have solved the crystal structure of CPA complexed with L-1 up to 1.85 A resolution. In CPA-L-1 complex, the phenyl ring is fitted in the substrate recognition pocket at the S, subsite, and the carboxylate forms bifurcated hydrogen bonds with the guanidinium moiety of Arg-145 and Arg-127 and a hydrogen bond with the phenolic hydroxyl of the down-positioned Tyr-248. The carbonyl oxygen of L-1 does coordinate to the active site zinc ion of CPA as expectedly. Unexpectedly, the terminal hydroxyl group of L-1 is engaged in hydrogen bonding with carbonyl oxygen of Ser-197 instead of coordinating to the active site zinc ion. (C) 2009 Guan Rong Tian. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All fights reserved.

  DOI：

  10.1016/j.cclet.2009.09.005

文献信息

• Heterocyclic modulators of PKB
  申请人：ZENG Qingping

  公开号：US20090275592A1

  公开（公告）日：2009-11-05

  The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种公式I的杂环化合物及其组合物，其中变量具有本文所提供的定义，其在治疗由蛋白激酶B（PKB）介导的疾病方面具有用途。本发明还涉及这种化合物和组合物在治疗与异常细胞生长、癌症、炎症和代谢紊乱相关的疾病状态方面的治疗用途。
• HETEROCYCLIC MODULATORS OF PKB
  申请人：Amgen Inc.

  公开号：EP2173728A2

  公开（公告）日：2010-04-14
• US7897619B2
  申请人：——

  公开号：US7897619B2

  公开（公告）日：2011-03-01
• [EN] HETEROCYCLIC MODULATORS OF PKB<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE PKB
  申请人：AMGEN INC

  公开号：WO2009011880A2

  公开（公告）日：2009-01-22

  The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein Formula (I). The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.